dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Muro, Kei |
dc.contributor.author | Salinardi, Taylor |
dc.contributor.author | Singh, Arvind Rup |
dc.contributor.author | Macarulla Mercadé, Teresa |
dc.date.accessioned | 2021-09-20T13:06:24Z |
dc.date.available | 2021-09-20T13:06:24Z |
dc.date.issued | 2020-03-31 |
dc.identifier.citation | Muro K, Salinardi T, Singh AR, Macarulla T. Safety of Aflibercept in Metastatic Colorectal Cancer: A Literature Review and Expert Perspective on Clinical and Real-World Data. Cancers. 2020 Mar 31;12:844. |
dc.identifier.issn | 2072-6694 |
dc.identifier.uri | https://hdl.handle.net/11351/6333 |
dc.description | Aflibercept; Anti-angiogenic therapy; Colorectal cancer |
dc.description.abstract | Background: Metastatic colorectal cancer (mCRC) represents a substantial health burden globally and an increasing challenge in Asian countries. Treatment options include chemotherapy plus a vascular endothelial growth factor (VEGF) inhibitor (such as bevacizumab, aflibercept or ramucirumab), or anti-epidermal growth factor receptor (EGFR) therapies. Aflibercept, a recombinant fusion protein, has been approved for treatment of mCRC in combination with FOLFIRI for patients whose disease progresses during or after treatment with an oxaliplatin-containing regimen, based on its efficacy and tolerability profile in clinical trials. This report aims to provide an overview of both clinical and real-world evidence and experience on the use of aflibercept in routine clinical practice, with a focus on European, American and Asian populations. Methods: A literature search was conducted in PubMed (on 28th February 2019) using the search terms ("aflibercept") and ("Colorectal"OR"CRC") to identify publications containing information on aflibercept-containing regimens. Results: The adverse events (AE) profile was similar between geographical locations. Across trials, real-world and retrospective studies, grade ≥ 3 hypertension and proteinuria were amongst the most frequently reported AEs. Conclusions: The safety profile of aflibercept is generally manageable and comparable across various geographic locations. |
dc.language.iso | eng |
dc.publisher | MDPI |
dc.relation.ispartofseries | Cancers;12 |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Proteïnes recombinants |
dc.subject | Còlon - Càncer - Tractament |
dc.subject | Recte - Càncer - Tractament |
dc.subject.mesh | Colorectal Neoplasms |
dc.subject.mesh | /drug therapy |
dc.subject.mesh | Recombinant Fusion Proteins |
dc.title | Safety of Aflibercept in Metastatic Colorectal Cancer: A Literature Review and Expert Perspective on Clinical and Real-World Data |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.3390/cancers12040844 |
dc.subject.decs | neoplasias colorrectales |
dc.subject.decs | /farmacoterapia |
dc.subject.decs | proteínas de fusión recombinantes |
dc.relation.publishversion | https://doi.org/10.3390/cancers12040844 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Muro K] Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya 464-8681, Japan. [Salinardi T, Singh AR] Global Medical Oncology, Sanofi, Boston, MA 02142, USA. [Macarulla T] Grup de Tumors gastrointestinals, Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. IOB, Barcelona, Spain |
dc.identifier.pmid | 32244546 |
dc.identifier.pmid | 000535587400073 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |